

Checkpoint Inhibitors: Global Markets

<https://marketpublishers.com/r/CD33E7E1B14EN.html>

Date: October 2018

Pages: 141

Price: US\$ 1,250.00 (Single User License)

ID: CD33E7E1B14EN

Abstracts

Report Scope:

This report on checkpoint inhibitors provides a detailed analysis of the market based on approved clinical and preclinical developmental candidates that target PD-1/PD-L1, CTLA-4, IDO-1, LAG-3, TIM-3 and CD47/SIRP?. The report analyzes the market trends, key medical needs and provides insights into recent advances in the modulation of checkpoint inhibition in the treatment of cancer through the development of fully human monoclonal antibodies, bispecific antibodies, fusion proteins and Chimeric Antigen Receptor (CAR) T cells.

Report Includes

21 data tables and 43 additional tables

An overview of the global market for checkpoint inhibitors

Analyses of global market trends, with data from 2017 to 2018, and projections of compound annual growth rates (CAGRs) through 2023

Discussion of the market landscape and innovative strategies, and the areas of unmet medical needs

Information on the biomarker development, immune modulation, innovative delivery technologies, and the future landscape

Market analysis for CP inhibitors, including PD-1/PD-L1 agents, CTLA-4 agents, TIM-3 agents, LAG-3 agents, IDO-1 agents, and SIRP? agents

Comprehensive company profiles of major players in the industry, including Agenus, Inc., BeiGene, BIOCAD, Forty Seven, Inc., Seattle Genetics, Inc., Shanghai Cell Therapy, Tesaro, Inc. and Xencor

Contents

CHAPTER 1 INTRODUCTION

Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports

CHAPTER 2 SUMMARY AND HIGHLIGHTS

CHAPTER 3 IMMUNO-ONCOLOGY MARKET AND CHECKPOINT MARKET STATISTICS

Immuno-Oncology
Co-Stimulatory Immune Checkpoint Targets
Inhibitory Immune Checkpoint Targets
Immunometabolic Modulatory Targets
Unmet Medical Needs
New Biomarkers to Stratify Patients
Relapse/Refractory Patients
Treatment Efficacy and Tolerability
Innovative Strategies
Emerging New Checkpoint Inhibitors
New Combinations
Novel Targeted Approaches
Humanized Monoclonal Antibodies
Bispecific Agents
CAR-T Cells
Current Market Landscape
Marketed Checkpoint Inhibitors
Developmental Checkpoint Inhibitors

CHAPTER 4 PD-1/PD-L1 AGENTS

Checkpoint Inhibitors: Global Markets

Introduction

Marketed

Pembrolizumab (Keytruda), Merck & Co.

Companion Diagnostic

Clinical Trial Program

Pembrolizumab Forecasts

Nivolumab (Opdivo), BMS

Companion Diagnostic

Clinical Trial Program

Nivolumab Forecasts

Atezolizumab (Tecentriq), Genentech

Companion Diagnostic

Clinical Trial Program

Atezolizumab Forecasts

Avelumab (Bavencio), Merck KGaA/Pfizer

Companion Diagnostic

Clinical Trial Program

Avelumab Forecasts

Durvalumab (Imfinzi), AstraZeneca

Companion Diagnostic

Clinical Trial Program

Durvalumab Forecasts

Cemiplimab (Libtayo), Regeneron/Sanofi

Clinical Programs Phase

Spartalizumab, Novartis

Tislelizumab, BeiGene

Clinical Programs Phase

INCMGA0012, Incyte/MacroGenics

LY3300054, Eli Lilly

Clinical Programs Phase

BI 754091, Boehringer Ingelheim

CA-170, Curis/Aurigene

CS1001, CStone Pharmaceuticals

FS118, Merck KGaA/F-Star

Preclinical Programs

aCD27xaPD-L1, Celldex

MEDI1109, AstraZeneca

XmAb20717 and XmAb23104, Xencor

Market Forecasts

CHAPTER 5 CTLA-4

Introduction

Marketed Drugs

Yervoy (ipilimumab), BMS

Clinical Programs Phase

Tremelimumab, Astra Zeneca

Clinical Programs Phase 1/2

Anti-CTLA-4/PD-1 Expressing MUC1-CAR-T, Shanghai Cell Therapy

Clinical Programs Phase

AGEN-1884, Agenus

BCD-145, Biocad

CS1002, CStone Pharmaceuticals

REGN4659, Regeneron Pharmaceuticals

Market Forecasts

CHAPTER 6 IDO-1

Introduction

IDO-1 Developmental Therapies

Clinical Programs Phase

Epacadostat, Incyte

Clinical Programs Phase

BMS 986205, Bristol-Myers Squibb

EOS200271, iTeos Therapeutics

Indoximod (NLG-001) and Navoximod (NLG 919, GDC-0919, R6078), NewLink

Genetics

KHK2455, Kyowa Kirin

LY3381916, Eli Lilly

Preclinical Programs

Market Forecasts

CHAPTER 7 LAG-3

Introduction

LAG-3 Developmental Therapies

Clinical Programs Phase 2/3

Relatlimab (BMS-986016), BMS
Clinical Programs Phase
LAG525 (IMP701), Novartis/Immuntep (Prima BioMed)
Eftilagimod Alpha (IMP321), Immuntep (Prima BioMed)
BI 754111, Boehringer Ingelheim
FS118, Merck KGaA/ F-star
Sym022, Shire/Symphogen A/S
TSR-033, Tesaro/Anaptys Bio
XmAb22841, Xencor
Preclinical Programs
INCAGN02385, Incyte/Agenus
Market Forecasts

CHAPTER 8 TIM-1,3

Introduction
TIM-1,3 Developmental Therapies
Clinical Programs Phase
Bavituximab, Merck Sharp & Dohme/Oncologie International
Clinical Programs Phase 1/2
CDX-014, Celldex Therapeutics/Seattle Genetics
MGB453 +/- Spartalizumab, Novartis
Clinical Programs Phase
LY3321367 +/- LY3300054, Eli Lilly
TSR-022 +/- TSR-042, Tesaro/AnaptysBio
Preclinical Programs
CA-327 (AUPM-327), Curis/Aurigene
ENUM005, Enumeral Biomedical
JNJ-64158120, Johnson & Johnson
LY3321367, Eli Lilly
STI-600, Sorrento Therapeutics
Sym016, Symphogen A/S
Market Forecasts

CHAPTER 9 CD47/SIRPA

Introduction
CD47-SIRPa Developmental Therapies
Clinical Phase 1/2

5F9, FORTY SEVEN INC
Clinical Programs Phase
ALX148, ALX Oncology
CC-90002, Celgene/InhibRx
SRF231, Surface Oncology
TTI-621, Trillium
TTI-622, Trillium
Preclinical Programs
OSE-172, Boeringher Ingelheim/ OSE Immunotherapeutics
INCAGN2390, Incyte/Agenus
Market Forecasts

CHAPTER 10 COMPANY PROFILES

ALX ONCOLOGY
AGENUS INC.
ANAPTYS BIO
BEIGENE
BIOCAD
CSTONE PHARMACEUTICALS
CRESCENDO BIOLOGICS LTD.
F-STAR BIOTECHNOLOGY
FORTY SEVEN, INC.
IMMUTEP, LTD.
INHIBRX
MACROGENICS, INC.
OSE IMMUNOTHERAPEUTIC
REGENERON PHARMACEUTICALS, INC.
SEATTLE GENETICS, INC.
SORRENTO THERAPEUTICS, INC.
SHANGHAI CELL THERAPY
SYMPHOGEN A/S
SURFACE ONCOLOGY
TESARO, INC.
TRILLIUM THERAPEUTICS
XENCOR

CHAPTER 11 APPENDIX A: LIST OF ABBREVIATIONS

CHAPTER 12 APPENDIX B: GLOSSARY OF TERMS

CHAPTER 13 APPENDIX C: SOURCES

List Of Tables

LIST OF TABLES

Summary Table: Global Market for Checkpoint Inhibitors, by Drug Class, Through 2023

Table 1: Adverse Events Associated with Immune-Checkpoint Blockade

Table 2: Global Market for Marketed Checkpoint Inhibitors, by Drug Target, Through 2023

Table 3: Global Market for Developmental Checkpoint Inhibitors, by Drug Target, Through 2023

Table 4: Comparison of PD-L1-PD-L2 ligands

Table 5: Summary of Anti-PD-1/PD-L1 Therapies Approved Indications

Table 6: PD-1/PD-L1 Agents in Development

Table 7: Pembrolizumab Approved Indications

Table 8: Global Market for Pembrolizumab, by Region, Through 2023

Table 9: Global Market for Pembrolizumab, by Indication, Through 2023

Table 10: Nivolumab Approved Indications

Table 11: Global Market for Nivolumab, by Region, Through 2023

Table 12: Global Market for Nivolumab, by Indication, Through 2023

Table 13: Atezolizumab Approved Indications

Table 14: Global Market for Atezolizumab, by Region, Through 2023

Table 15: Global Market for Atezolizumab, by Indication, Through 2023

Table 16: Avelumab Approved Indications

Table 17: Global Market for Avelumab, by Region, Through 2023

Table 18: Global Market for Avelumab, by Indication, Through 2023

Table 19: Durvalumab Approved Indications

Table 20: Global Market for Durvalumab, by Region, Through 2023

Table 21: Global Market for Duvalumab, by Indication, Through 2023

Table 22: Regeneron's NSCLC Development Program

Table 23: Global Market for Cemiplimab, by Region, Through 2023

Table 24: Global Market for Cemiplimab, by Indication, Through 2023

Table 25: Clinical Trials Evaluating Tislelizumab

Table 26: Clinical Trials Evaluating INCMGA00012

Table 27: Global Market for anti-PD-1/PD-L1 Therapies, by Product, Through 2023

Table 28: CTLA-4 Agents in Development

Table 29: Global Market for Anti-CTLA-4 Therapies, by Product, Through 2023

Table 30: Summary of Anti-IDO-1 Developmental Programs

Table 31: Clinical Trials Evaluating Epacadostat

Table 32: Clinical Trials Evaluating Navoximod (GDC-0919)

Table 33: Global Market for anti-IDO-1 Therapies, by Product, Through 2023

Table 34: Anti- LAG-3 Therapies in Development

Table 35: Clinical Trials Evaluating Relatlimab

Table 36: Clinical Trials Evaluating LAG525

Table 37: Clinical Trials Evaluating IMP321

Table 38: Clinical Trials Evaluating BI 754111

Table 39: Clinical Trials Evaluating FS118

Table 40: Clinical Trials Evaluating Sym022

Table 41: Clinical Trials Evaluating TSR-033

Table 42: Global Market for anti-LAG-3 Therapies, by Product, Through 2023

Table 43: TIM-1,3 Agents in Development

Table 44: Global Market for Anti-TIM-1,3 Therapies, by Product, Through 2023

Table 45: T-Cell and Macrophages Characteristics

Table 46: Clinical Trials Evaluating CD47-SIRP? Targeted Therapies

Table 47: Clinical Trials Evaluating 5F9

Table 48: Clinical Trials Evaluating ALX148

Table 49: Clinical Trials Evaluating C-9002

Table 50: Clinical Trials Evaluating C-9002

Table 51: Clinical Trials Evaluating TTI-621

Table 52: Clinical Trials Evaluating TTI-622

Table 53: Global Market for anti-CD47-SIRP? Therapies, by Product, Through 2023

Table 54: Abbreviations Used in Checkpoint Inhibitors

Table 55: Glossary of Terms

Table 56: Checkpoint Inhibitors Sources

Table 57: CHAPTER 2 Sources

Table 58: CHAPTER 3 Sources

Table 59: CHAPTER 4 Sources

Table 60: CHAPTER 5 Sources

Table 61: CHAPTER 6 Sources

Table 62: CHAPTER 7 Sources

Table 63: CHAPTER 8 Sources

List Of Figures

LIST OF FIGURES

Summary Figure: Global Market for Checkpoint Inhibitors, by Drug Class, 2017-2023

Figure 1: Potential Targets for Checkpoint Inhibition in Clinical Evaluation

Figure 2: Global Market for Marketed Checkpoint Inhibitors, by Drug Target, 2017-2023

Figure 3: Global Market for Developmental Checkpoint Inhibitors, by Drug Target, 2017-2023

Figure 4: Pembrolizumab Comprehensive Clinical Trial Programs, by Status

Figure 5: Pembrolizumab Comprehensive Clinical Trial Programs, by Therapy

Figure 6: Pembrolizumab Comprehensive Clinical Trial Programs, by Cancer Type

Figure 7: Global Market for Pembrolizumab, by Region, 2017-2023

Figure 8: Nivolumab Comprehensive Clinical Trial Programs, by Status

Figure 9: Nivolumab Comprehensive Clinical Trial Programs, by Therapy

Figure 10: Nivolumab Comprehensive Clinical Trial Programs, by Cancer Type

Figure 11: Global Market for Nivolumab, by Region, 2017-2023

Figure 12: Atezolizumab Comprehensive Clinical Trial Programs, by Status

Figure 13: Atezolizumab Comprehensive Clinical Trial Programs, by Therapy

Figure 14: Atezolizumab Comprehensive Clinical Trial Programs, by Cancer Type

Figure 15: Global Market for Atezolizumab, by Region, 2017-2023

Figure 16: Avelumab Comprehensive Clinical Trial Programs, by Status

Figure 17: Avelumab Comprehensive Clinical Trial Programs, by Therapy

Figure 18: Avelumab Comprehensive Clinical Trial Programs, by Cancer Type

Figure 19: Global Market for Avelumab, by Region, 2017-2023

Figure 20: Durvalumab Comprehensive Clinical Trial Programs, by Status

Figure 21: Durvalumab Comprehensive Clinical Trial Programs, by Therapy

Figure 22: Durvalumab Comprehensive Clinical Trial Programs, by Cancer Type

Figure 23: Global Market for Durvalumab, by Region, 2017-2023

Figure 24: Global Market for Cemiplimab, by Region, 2017-2023

Figure 25: Global Market for anti-PD-1/PD-L1, by Product, 2017-2023

Figure 26: Signaling Molecules Involved in CD28 and CTLA-4 Function

Figure 27: Fab Fragment of ipilimumab (blue) Binding CTLA-4 (green)

Figure 28: Global Market for Anti-CTLA-4 Therapies, by Product, 2017-2023

Figure 29: Schematic of Mechanism of Action of IDO-1 Inhibition on Tryptophan (Trp) Catabolism in Cancer

Figure 30: Structure of Epacadostat

Figure 31: Structure of BMS-986205

Figure 32: Structure of A) Innoximod and B) navoximod

Figure 33: Global Market for anti-IDO-1 Therapies, by Product, 2017-2023

Figure 34: Global Market for Anti-LAG3 Therapies, by Product, 2017-2023

Figure 35: Schematic of Mechanism of Action of TIM-3 in T-Cell Activation and Synergistic Effect on PD-1 Inhibition

Figure 36: Global Market for Anti-TIM-1,3 Therapies, by Product, 2017-2023

Figure 37: Mechanism of Action of Anti-CD47/SIRP α Therapies

Figure 38: Structure of ALX148

Figure 39: Structure of TTI-621

Figure 40: Structure of TTI-622

Figure 41: Global Market for anti-CD47-SIRP α , by Product, 2017-2023

I would like to order

Product name: Checkpoint Inhibitors: Global Markets

Product link: <https://marketpublishers.com/r/CD33E7E1B14EN.html>

Price: US\$ 1,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CD33E7E1B14EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970